Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Redefining penems.

Axel Dalhoff1, Nebojsa Janjic, Roger Echols

  • 1University Hospital Schleswig-Holstein, Campus Kiel, Institute for Infection Medicine, Brunswiker Str 4, D-24105 Kiel, Germany. Adalhoff@t-online.de

Biochemical Pharmacology
|January 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probing molecular diversity and ultrastructure of brain cells with fluorescent aptamers.

Nature communications·2026
Same author

Multiomics characterization of acute child illness and mortality in Africa and South Asia.

Nature communications·2026
Same author

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.

The Lancet. Infectious diseases·2026
Same author

Proteomic profiles in the aqueous following anti-vegf therapy in treatment naïve neovascular age-related macular degeneration.

Clinical proteomics·2025
Same author

Activated GDF11/8 subforms predict cardiovascular events and mortality in humans.

Nature communications·2025
Same author

Hospital Mortality in Acute Decompensation of Alcoholic Liver Cirrhosis: Can Novel Survival Markers Outperform Traditional Ones?

Journal of clinical medicine·2024
Same journal

Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology.

Biochemical pharmacology·2026
Same journal

hIMB1636-LDM, a novel anti-TROP2 ADC, exerts potent antitumor efficacy in pancreatic cancer via direct cytotoxicity and immune activation.

Biochemical pharmacology·2026
Same journal

CD55 glycosylation promotes ferroptotic stress tolerance in CD55-high triple-negative breast cancer.

Biochemical pharmacology·2026
Same journal

The role of Piezo1 in skeletal muscle physiology and pathology: from mechanosensing to precision therapy.

Biochemical pharmacology·2026
Same journal

Notch signaling in anti-VEGF resistant arteriolar choroidal neovascularization.

Biochemical pharmacology·2026
Same journal

Methylated SNHG3 lncRNA counteracts PSMD4-inhibited angiogenesis by HnRNPA2B1 SUMOylation in peripheral arterial disease.

Biochemical pharmacology·2026
See all related articles

Penem antibiotics offer broad-spectrum activity and stability against beta-lactamases, addressing key resistance issues. Faropenem, a penem, is effective for community infections and sequential therapy without compromising carbapenem effectiveness.

Area of Science:

  • Antimicrobial chemotherapy
  • Medicinal chemistry
  • Infectious disease

Background:

  • Beta-lactam antibiotics face significant resistance from enzymes like beta-lactamases.
  • Penems represent a class of beta-lactam antibiotics with broad antibacterial activity and inherent stability.
  • Carbapenems target hospital pathogens, while penems are effective against community pathogens.

Purpose of the Study:

  • To evaluate the potential of penem antibiotics in combating antimicrobial resistance.
  • To highlight the advantages of faropenem, the sole available penem, in clinical settings.

Main Methods:

  • Review of the pharmacological properties of penem antibiotics.
  • Analysis of resistance mechanisms against beta-lactam antibiotics.
  • Assessment of faropenem's clinical utility and resistance profile.

Related Experiment Videos

Main Results:

  • Penems exhibit broad-spectrum activity and stability against common beta-lactamases (ESBL, AmpC).
  • Faropenem demonstrates a low propensity for resistance development and beta-lactamase induction.
  • Faropenem effectively treats community-acquired infections and facilitates sequential therapy.

Conclusions:

  • Penems, particularly faropenem, are valuable agents for managing infections and combating antimicrobial resistance.
  • Faropenem's profile supports its use in community settings and as a step-down therapy, preserving carbapenem efficacy.
  • The penem class offers a promising strategy to address beta-lactam resistance challenges.